Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) jumped 19% on Thursday after the company announced that a new patent for its GIMOTI nasal spray has been included in the FDA’s Orange Book.
The specialty pharmaceutical firm, which develops treatments for gastrointestinal conditions, revealed that U.S. Patent No. 12,377,064—covering the use of GIMOTI (metoclopramide) nasal spray for patients with moderate to severe gastroparesis—has now been listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations.
This newly listed patent is expected to expire on November 17, 2038, effectively extending protection by roughly eight years beyond the company’s previous last-to-expire Orange Book patent, which was set to lapse on May 15, 2030.
“We believe the listed patent shows our commitment to developing innovative products that expand options for patients and providers, while also protecting our hard work and investment in innovation,” said Matt D’Onofrio, Chief Executive Officer of Evoke Pharma.
The company noted that the patent supports its long-term plan to maximize GIMOTI’s commercial life and ensures continued patient access to a non-oral treatment for diabetic gastroparesis, while safeguarding its investment in innovation.
GIMOTI is a nasal spray version of metoclopramide designed for patients with gastroparesis, a disorder that slows stomach emptying and can cause nausea, vomiting, and abdominal discomfort.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.